These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37972067)

  • 21. Intranasal CRMP2-Ubc9 inhibitor regulates Na V 1.7 to alleviate trigeminal neuropathic pain.
    Loya-Lopez SI; Allen HN; Duran P; Calderon-Rivera A; Gomez K; Kumar U; Shields R; Zeng R; Dwivedi A; Saurabh S; Korczeniewska OA; Khanna R
    Pain; 2024 Mar; 165(3):573-588. PubMed ID: 37751532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.
    Ju W; Li Q; Wilson SM; Brittain JM; Meroueh L; Khanna R
    Channels (Austin); 2013; 7(3):153-9. PubMed ID: 23510938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.
    Feldman P; Khanna R
    Neurosci Lett; 2013 Dec; 557 Pt A(0 0):27-36. PubMed ID: 23831344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain.
    François-Moutal L; Dustrude ET; Wang Y; Brustovetsky T; Dorame A; Ju W; Moutal A; Perez-Miller S; Brustovetsky N; Gokhale V; Khanna M; Khanna R
    Pain; 2018 Oct; 159(10):2115-2127. PubMed ID: 29847471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy.
    Khanna R; Yu J; Yang X; Moutal A; Chefdeville A; Gokhale V; Shuja Z; Chew LA; Bellampalli SS; Luo S; François-Moutal L; Serafini MJ; Ha T; Perez-Miller S; Park KD; Patwardhan AM; Streicher JM; Colecraft HM; Khanna M
    Pain; 2019 Jul; 160(7):1644-1661. PubMed ID: 30933958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A next generation peripherally restricted Cavα2δ-1 ligand with inhibitory action on Cav2.2 channels and utility in neuropathic pain.
    Kricek F; Ruf C; Meghani P; Souza IA; Gandini MA; Zamponi GW; Skouteris G
    Biomed Pharmacother; 2024 May; 174():116472. PubMed ID: 38531121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy via block of N- and T-type calcium channels.
    Bellampalli SS; Ji Y; Moutal A; Cai S; Wijeratne EMK; Gandini MA; Yu J; Chefdeville A; Dorame A; Chew LA; Madura CL; Luo S; Molnar G; Khanna M; Streicher JM; Zamponi GW; Gunatilaka AAL; Khanna R
    Pain; 2019 Jan; 160(1):117-135. PubMed ID: 30169422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex.
    Wilson SM; Brittain JM; Piekarz AD; Ballard CJ; Ripsch MS; Cummins TR; Hurley JH; Khanna M; Hammes NM; Samuels BC; White FA; Khanna R
    Channels (Austin); 2011; 5(5):449-56. PubMed ID: 21829088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel α-conopeptide Eu1.6 inhibits N-type (Ca
    Liu Z; Bartels P; Sadeghi M; Du T; Dai Q; Zhu C; Yu S; Wang S; Dong M; Sun T; Guo J; Peng S; Jiang L; Adams DJ; Dai Q
    Sci Rep; 2018 Jan; 8(1):1004. PubMed ID: 29343689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy.
    Piekarz AD; Due MR; Khanna M; Wang B; Ripsch MS; Wang R; Meroueh SO; Vasko MR; White FA; Khanna R
    Mol Pain; 2012 Jul; 8():54. PubMed ID: 22828369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An integrated multiassay approach to the discovery of small-molecule N-type voltage-gated calcium channel antagonists.
    Finley MF; Lubin ML; Neeper MP; Beck E; Liu Y; Flores CM; Qin N
    Assay Drug Dev Technol; 2010 Dec; 8(6):685-94. PubMed ID: 21050074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels.
    Zhou Y; Cai S; Moutal A; Yu J; Gómez K; Madura CL; Shan Z; Pham NYN; Serafini MJ; Dorame A; Scott DD; François-Moutal L; Perez-Miller S; Patek M; Khanna M; Khanna R
    ACS Chem Neurosci; 2019 Dec; 10(12):4834-4846. PubMed ID: 31697467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upregulation of N-type calcium channels in the soma of uninjured dorsal root ganglion neurons contributes to neuropathic pain by increasing neuronal excitability following peripheral nerve injury.
    Yang J; Xie MX; Hu L; Wang XF; Mai JZ; Li YY; Wu N; Zhang C; Li J; Pang RP; Liu XG
    Brain Behav Immun; 2018 Jul; 71():52-65. PubMed ID: 29709527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.
    Moutal A; Yang X; Li W; Gilbraith KB; Luo S; Cai S; François-Moutal L; Chew LA; Yeon SK; Bellampalli SS; Qu C; Xie JY; Ibrahim MM; Khanna M; Park KD; Porreca F; Khanna R
    Pain; 2017 Dec; 158(12):2301-2319. PubMed ID: 28809766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex.
    Brittain JM; Duarte DB; Wilson SM; Zhu W; Ballard C; Johnson PL; Liu N; Xiong W; Ripsch MS; Wang Y; Fehrenbacher JC; Fitz SD; Khanna M; Park CK; Schmutzler BS; Cheon BM; Due MR; Brustovetsky T; Ashpole NM; Hudmon A; Meroueh SO; Hingtgen CM; Brustovetsky N; Ji RR; Hurley JH; Jin X; Shekhar A; Xu XM; Oxford GS; Vasko MR; White FA; Khanna R
    Nat Med; 2011 Jun; 17(7):822-9. PubMed ID: 21642979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Neurexins Together with α2δ-1 Auxiliary Subunits Regulate Ca
    Brockhaus J; Schreitmüller M; Repetto D; Klatt O; Reissner C; Elmslie K; Heine M; Missler M
    J Neurosci; 2018 Sep; 38(38):8277-8294. PubMed ID: 30104341
    [TBL] [Abstract][Full Text] [Related]  

  • 37. α-Conotoxin Vc1.1 inhibits human dorsal root ganglion neuroexcitability and mouse colonic nociception via GABA
    Castro J; Harrington AM; Garcia-Caraballo S; Maddern J; Grundy L; Zhang J; Page G; Miller PE; Craik DJ; Adams DJ; Brierley SM
    Gut; 2017 Jun; 66(6):1083-1094. PubMed ID: 26887818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional exofacially tagged N-type calcium channels elucidate the interaction with auxiliary α2δ-1 subunits.
    Cassidy JS; Ferron L; Kadurin I; Pratt WS; Dolphin AC
    Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8979-84. PubMed ID: 24889613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-voltage long-duration pulsed radiofrequency attenuates neuropathic pain in CCI rats by inhibiting Cav2.2 in spinal dorsal horn and dorsal root ganglion.
    Cai Z; Quan L; Chang X; Qiu Z; Zhou H
    Brain Res; 2022 Jun; 1785():147892. PubMed ID: 35341732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-allodynic effect of 2-(aminomethyl)adamantane-1-carboxylic acid in a rat model of neuropathic pain: a mechanism dependent on CaV2.2 channel inhibition.
    Zoidis G; Sandoval A; Pineda-Farias JB; Granados-Soto V; Felix R
    Bioorg Med Chem; 2014 Mar; 22(6):1797-803. PubMed ID: 24582401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.